Pliant Therapeutics Under Investigation for Securities Violations

LOS ANGELES, Feb. 20, 2025 /PRNewswire/ — The Schall Law Firm, a national firm specializing in shareholder rights litigation, has announced that it is investigating potential claims on behalf of investors in Pliant Therapeutics, Inc. (“Pliant” or “the Company”) PLRX for possible violations of securities laws.

The investigation centers around whether Pliant made false or misleading statements and/or failed to disclose important information to investors. A press release from Pliant on February 7, 2025 announced a major development: following a review by the independent Data Safety Monitoring Board (DSMB), the Company voluntarily paused enrollment in its BEACON-IPF Phase 2b trial for bexotegrast, which targets idiopathic pulmonary fibrosis (IPF). As a consequence of this news, Pliant’s shares plummeted by 60.59% on February 10, 2025.

Shareholders who experienced losses are urged to take action and may click here to participate in the investigation.

For more information about your rights or to discuss your situation free of charge, please contact Brian Schall at the Schall Law Firm, located at 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, by calling 310-301-3335. You can also connect with the firm through its website at www.schallfirm.com, or by emailing bschaall@schallfirm.com.

The Schall Law Firm represents investors worldwide and focuses on securities class action lawsuits and shareholder rights litigation.

This press release could be classified as Attorney Advertising under certain legal and ethical guidelines.

CONTACT:
The Schall Law Firm
Brian Schall, Esq.
310-301-3335
info@schallfirm.com
www.schallfirm.com

View original content to download multimedia: https://www.prnewswire.com/news-releases/plrx-investors-have-opportunity-to-join-pliant-therapeutics-inc-fraud-investigation-with-the-schall-law-firm-302381663.html

SOURCE The Schall Law Firm